A recent collaborative meta-analysis of 13 RCTs led by the ‘SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium’ (SMART-C) was conducted to provide solid effect estimates of SGLT2i use in patients without diabetes (Table 1) [4]. Here, SLC5A2 is linked to diabetes mellitus.